Posted by Michael Wonder on 23 Jan 2023
TheracosBio announces FDA approval of Brenzavvy (bexagliflozin) for the treatment of adults with type 2 diabetes
23 January 2023 - Once daily, oral SGLT2 inhibitor shown to reduce blood sugar and improve glycemic control as an adjunct to diet and exercise.
TheracosBio today announced that the US FDA has approved Brenzavvy (bexagliflozin), an oral sodium glucose co-transporter 2 (SGLT2) inhibitor.
